Valeant Includes OTCs In Bid For Dramatic Growth By 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
The Ontario-based firm has its sights set on becoming a top-15 pharma company with a $50 billion market capitalization by the end of 2013. Emerging markets and consumer health products, including the recent iNova and Fleming deals, play a big part in Valeant’s plans.
You may also be interested in...
Valeant Keeps Door Open For Consumer Products Acquisitions
The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.
Valeant Keeps Door Open For Consumer Products Acquisitions
The specialty pharmaceutical firm’s consumer products portfolio has grown with the closing of its ophthalmology firm Bausch & Lomb acquisition. Valeant is not ruling out more acquisitions in the consumer products space, CEO J. Michael Pearson says.
Deals Of The Week: Allena/Althea, Almirall/Menarini, Bausch & Lomb/Ista
Earn-outs are more frequent in biotech M&A deals these days, but private investors also are becoming more savvy in terms of tracking earn-outs and which ones are more likely than others to pay off.